{
    "clinical_study": {
        "@rank": "166584", 
        "arm_group": {
            "arm_group_label": "Debio1143", 
            "arm_group_type": "Experimental", 
            "description": "Debio1143"
        }, 
        "brief_summary": {
            "textblock": "Phase I study (dose escalation) To determine the maximum tolerated dose (MTD) of Debio 1143\n      in combination with concurrent CRT in patients with LA-SCCHN."
        }, 
        "brief_title": "Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Squamous Cell Carcinoma of the Head and Neck", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Squamous Cell", 
                "Head and Neck Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Willing and able to sign a written informed consent;\n\n          2. Male or female \u226518 \u226475 years of age.\n\n          3. Histologically confirmed diagnosis of previously untreated LA-SCCHN (Stage III, IVa\n             and IVb according to the American Joint Committee on Cancer Staging System) of one or\n             more of the following sites: oral cavity, oropharynx, hypopharynx and larynx;\n\n          4. Tumour HPV negative status for oropharynx cancer patients, determined by p16 IHC;\n\n          5. Positive smoking history (> 10 packs/year);\n\n          6. Availability of pre-treatment tumour sample (optional for Phase I; mandatory for\n             Phase II [10-20 tumour slides]);\n\n          7. Measurable disease by the RECIST 1.1 criteria;\n\n          8. Negative medical history of Hepatitis B and Hepatitis C;\n\n          9. Women of child-bearing potential:\n\n               1. Negative serum pregnancy test at screening;\n\n               2. Agreement to use appropriate contraception methods from study entry to 6 months\n                  after the last day of treatment. Agreement to use contraception methods from her\n                  male partner.\n\n         10. Male patients agree to use contraception methods from study entry to 6 months after\n             the last day of treatment;\n\n         11. ECOG performance status 0 or 1\n\n         12. Subjects must have adequate haematological, renal and hepatic function; calculated\n             creatinine clearance \u2265 60 mL/min as determined by the modified method of Cockcroft\n             and Gault or by the EDTA method, absolute neutrophil count\n\n             \u22651 500/\u03bcL, platelets \u2265100 000/\u03bcL, haemoglobin \u2265 10 g/dL, aspartate (AST) and alanine\n             transaminase (ALT) less than 3 times the upper limit of the normal range (ULN), total\n             bilirubin \u2264 2.0 mg/dL, serum albumin >35 g/L.\n\n         13. QTcF interval \u2264 450 ms\n\n         14. Left ventricular ejection fraction (LVEF) within the institutional normal ranges as\n             measured by echocardiogram (ECHO) or multigated acquisition (MUGA) scan;\n\n         15. No prior treatment with IAP inhibitors.\n\n         16. No use or requirement for use of aspirin or aspirin containing products with > 100 mg\n             of aspirin per day;\n\n         17. No history of gastrointestinal bleeding within 1 year;\n\n         18. No active rheumatoid arthritis, active inflammatory bowel disease, chronic\n             infections, or any other disease or condition associated with chronic inflammation.\n\n        Exclusion Criteria:\n\n          1. Nasopharyngeal, paranasal sinuses, nasal cavity tumours or thyroid cancers;\n\n          2. Squamous cell cancer involving cervical neck nodes but from unknown primary site;\n\n          3. Metastatic disease;\n\n          4. Any prior or current treatment for invasive head and neck cancer of any kind. This\n             will include but is not limited to: prior tyrosine kinase inhibitors, prior\n             neoadjuvant therapy, prior surgical resection, or use of any investigational agent;\n\n          5. Weight loss of >10% during the last month;\n\n          6. Not compensated liver cirrhosis (Child-Pugh class C);\n\n          7. Gastro-intestinal disorders that could affect drug absorption (including, but not\n             limited to, major abdominal surgery, significant bowel obstruction, ulcerative\n             colitis, Crohn's disease);\n\n          8. Impaired bone turnover (serum C-terminal telopeptide [CTX] <300 pg/mL);1\n\n          9. Concurrent treatment with any other systemic anti-cancer therapy that is not\n             specified as part of the protocol regimen;\n\n         10. Concomitant treatment with any drug on the prohibited medication list (provided\n             separately);\n\n         11. Subjects with known history of uncontrolled or symptomatic angina, arrhythmias, or\n             congestive heart failure;\n\n         12. History of another malignancy within the last 5 years, with the exception of\n             completely resected basal or squamous cell skin cancer, or successfully treated\n             insitu carcinoma. History of non-invasive lesion or in-situ carcinoma, including in\n             the head and neck region that was successfully treated with surgery, photodynamic or\n             laser, will be permitted;\n\n         13. Peripheral neuropathy \u2265 grade 2;\n\n         14. Clinical hearing loss (to be confirmed by audiogram in doubtful cases);\n\n         15. If female, pregnant or lactating;\n\n         16. History of allergic reactions to appropriate antiemetics (e.g. 5-HT3 antagonists) to\n             be administered with chemotherapy;\n\n         17. The investigator considers the subject unfit for the study as a result of the medical\n             interview, physical examinations, or screening investigations."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "22", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02022098", 
            "org_study_id": "Debio 1143-201"
        }, 
        "intervention": [
            {
                "arm_group_label": "Debio1143", 
                "intervention_name": "Cisplatine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Debio1143", 
                "intervention_name": "Radiotherapy", 
                "intervention_type": "Radiation"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 20, 2013", 
        "link": {
            "url": "http://www.debiopharm.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75248"
                    }, 
                    "name": "Institut Curie"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toulouse", 
                        "country": "France", 
                        "zip": "31052"
                    }, 
                    "name": "Institut Claudius Regaud"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Villejuif", 
                        "country": "France", 
                        "zip": "94000"
                    }, 
                    "name": "Institut Gustave Roussy"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lausanne", 
                        "country": "Switzerland", 
                        "zip": "1011"
                    }, 
                    "name": "Centre Hospitalier Universitaire Vaudois (CHUV)"
                }, 
                "status": "Active, not recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "France", 
                "Switzerland"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I/II Randomized Study to Determine the Maximum Tolerated Dose, Safety, Pharmacokinetics and Antitumor Activity of Debio 1143 Combined With Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck.", 
        "other_outcome": [
            {
                "description": "Pharmacokinetic parameters (Cmax, AUC,  tmax,CL/F, Vss/F, ) of Debio 1143 alone and in combination withcisplatin and radiotherapy.", 
                "measure": "PK of Debio 1143 and cisplatin when administered in combination with radiation therapy, and explore the potential for drug-drug interactions of Debio 1143 in combination with cisplatin", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "description": "cIAP1 in PBMCs serum cytokeratin 18, IL-8, MCP-1 and TNF-alpha", 
                "measure": "Pharmacodynamic biomarkers of Debio 1143 activity in combination with concurrent CRT", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }
        ], 
        "overall_contact": {
            "last_name": "Claudio Zanna, MD", 
            "phone": "+41 21 321 01 11"
        }, 
        "overall_contact_backup": {
            "last_name": "Jer\u00f4me Douchain", 
            "phone": "+41 21 321 01 11"
        }, 
        "overall_official": {
            "affiliation": "CHUV, Lausanne", 
            "last_name": "Jean Bourhis, Pr", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament (ANSM)", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Safety profile of Debio 1143 in combination with concurrent CRT", 
            "measure": "Maximum tolerated dose (MTD) of Debio 1143 in combination with concurrent CRT in patients with LA-SCCHN.", 
            "safety_issue": "Yes", 
            "time_frame": "18 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02022098"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Anti-tumour activity of the recommended dose of Debio 1143 in combination with concurrent CRT in the study population", 
            "safety_issue": "No", 
            "time_frame": "18 months"
        }, 
        "source": "Debiopharm International SA", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Debiopharm International SA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}